Statins for Health & Longevity

Created on 11/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Opus 5.5 – Audit

Statins are inexpensive prescription oral medications that lower plaque-building cholesterol particles, used to prevent heart attacks and strokes. Trials show fewer such events and a modest survival gain, growing with longer, deeper cholesterol lowering; relative benefit appears similar at lower starting risk. Costs are mostly small: slightly higher blood sugar and diabetes diagnoses, mild muscle aches, minor liver enzyme changes, more bleeding strokes. Dementia, cancer or aging protection is unconfirmed. (Full Review)

Protocol

Trial-tested regimens
Rosuvastatin 10–20 mg or atorvastatin 40 mg
Taken once daily; atorvastatin tested at age 70 or older; pitavastatin 4 mg in HIV
Target-driven approach
LDL-C below 55, 70 or 100 mg/dL
Very high, high or moderate risk (ESC/EAS); Peter Attia treats apoB rather than LDL-C as the metric
Time of day
Simvastatin in the evening; rosuvastatin any time
Rosuvastatin with or without food; long-acting atorvastatin is commonly taken at a consistent time
Time to effect
Fewer coronary events
Grows over 3–5 years
In cholesterol-lowering trials of any type, reduction per 1 mmol/L grew from 11% in year one to 33% in years 3–5
LDL-C lowering
Within weeks
The rosuvastatin label allows checks from 4 weeks
Intended duration
Long-term, typically lifelong
Benefit accrues during each year taken; longer use yields larger absolute benefit

Benefits

Contraindications
  • Pregnancy (most advised to stop once pregnancy is recognized)
  • Breastfeeding
  • Acute liver failure or decompensated cirrhosis
  • Hypersensitivity to the specific statin or its inactive ingredients
  • Simvastatin users taking strong CYP3A4 inhibitors, gemfibrozil, cyclosporine or danazol
  • SLCO1B1 poor-function genotype (for simvastatin)
  • Prior statin-associated IMNM
Key Interactions
  • Strong CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors): raise simvastatin and atorvastatin levels
  • Gemfibrozil: raises myopathy risk; avoid with rosuvastatin, or cap at 10 mg
  • Cyclosporine and danazol: raise statin exposure and myopathy risk; rosuvastatin capped at 5 mg with cyclosporine
  • Calcium channel blockers (amlodipine), antiarrhythmics (amiodarone) and ranolazine: simvastatin capped at 20 mg, or 10 mg with verapamil, diltiazem or dronedarone
  • Other fibrates (fenofibrate): raise myopathy and rhabdomyolysis risk
  • Digoxin: atorvastatin raises digoxin levels
  • Colchicine: myopathy and rhabdomyolysis reported with atorvastatin
  • Ticagrelor: raises simvastatin and atorvastatin exposure; simvastatin not above 40 mg; rosuvastatin capped at 20 mg
  • Coumarin anticoagulants (warfarin): rosuvastatin and simvastatin raise the INR
  • Aluminum and magnesium hydroxide antacids (over the counter): rosuvastatin at least 2 hours before the antacid
  • Rifampin: reduces atorvastatin levels; simultaneous dosing
  • Oral contraceptives (ethinyl estradiol): atorvastatin raises their levels
  • Niacin at 1 g/day or more (prescription or supplement): myopathy with atorvastatin
  • Grapefruit juice: avoid with simvastatin; atorvastatin not with more than 1.2 liters daily
  • St John's wort (supplement): halves active simvastatin exposure
  • Green tea extract (supplement): lowers atorvastatin and rosuvastatin exposure
  • Psyllium fiber (supplement, additive): same LDL-C effect at a lower statin dose
  • Berberine (supplement, additive): lowers LDL-C more than either alone
  • Coenzyme Q10 (supplement): restores serum CoQ10 lowered by simvastatin
  • Ezetimibe (additive): further lowers LDL-C and cardiovascular events
Theoretical (inferred from mechanism)
  • Red yeast rice (supplement): raises myopathy risk without added benefit
  • Goldenseal (supplement): could raise simvastatin, lovastatin and atorvastatin levels and myopathy risk

Risk & Side Effects

  • High: Muscle pain, myopathy and rhabdomyolysis; new-onset type 2 diabetes; elevated liver enzymes
  • Medium: Hemorrhagic stroke; kidney and urinary abnormalities; fluid retention; herpes zoster
  • Low: Blunted fitness gains from aerobic training; cataract; glaucoma; memory and cognitive complaints; gynecomastia; autoimmune reactions; sleep disturbance and depression; fatigue, malaise and low energy; interstitial lung disease and breathlessness; allergic reactions; skin reactions; peripheral neuropathy; pancreatitis; tendon rupture; headache, dizziness, joint pain and digestive complaints; nasopharyngitis and urinary tract infection; blurred vision, tinnitus, nosebleeds and thyroid test changes; blood cell disorders; erectile dysfunction; amyotrophic lateral sclerosis
  • Speculative: CoQ10 depletion and mitochondrial effects

Monitoring

Marker Target Why
LDL-C <55 mg/dL very high risk, <70 high, <100 moderate Efficacy
ApoB <65 mg/dL very high risk, <80 high, <100 moderate Particle number
ALT 7–55 U/L; stop or reduce at ≥3× upper limit of normal Liver safety check
CK Women 26–192 U/L, men 39–308 U/L Muscle safety check when symptoms appear
HbA1c 4.0–5.6% Safety check; statins raise blood sugar
hsCRP JUPITER entry threshold ≥2.0 mg/L; track change from own baseline Inflammation
Urinalysis (protein, blood) Negative Safety check on high-dose rosuvastatin
Kidney function Not specified in the ER Baseline reference
Fasting glucose Not specified in the ER Paired with HbA1c
Bilirubin Not specified in the ER Paired with ALT if elevated

Cadence: Baseline panel before starting; lipids from 4 weeks after starting or changing dose, then every 3–12 months, with apoB alongside; HbA1c at 3–12 months, then yearly; ALT and CK only when symptoms or interacting drugs arise.

Qualitative Assessment

  • Muscle comfort and strength: new aches, cramps or weakness, especially on both sides and in the thighs, hips or shoulders
  • Exercise capacity: training progress, perceived exertion and recovery
  • Energy: daytime fatigue compared with baseline
  • Sleep quality: sleep onset, awakenings and dreams
  • Cognitive clarity: memory lapses or word-finding problems
  • Urine color: dark, cola-colored urine with muscle pain warrants urgent evaluation for rhabdomyolysis